Cargando…

Chemopreventive Effects of Concomitant or Individual Use of Statins, Aspirin, Metformin, and Angiotensin Drugs: A Study Using Claims Data of 23 Million Individuals

SIMPLE SUMMARY: Medications for chronic diseases, such as tatins, aspirin, metformin, and angiotensin-converting-enzyme inhibitors/angiotensin II receptor blockers, are studied for decades, and a vast body of previous research has suggested potential repurposing of these medications for cancer preve...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ching-Huan, Huang, Chih-Wei, Nguyen, Phung Anh, Lin, Ming-Chin, Yeh, Chih-Yang, Islam, Md. Mohaimenul, Rahmanti, Annisa Ristya, Yang, Hsuan-Chia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909564/
https://www.ncbi.nlm.nih.gov/pubmed/35267516
http://dx.doi.org/10.3390/cancers14051211
_version_ 1784666204882862080
author Wang, Ching-Huan
Huang, Chih-Wei
Nguyen, Phung Anh
Lin, Ming-Chin
Yeh, Chih-Yang
Islam, Md. Mohaimenul
Rahmanti, Annisa Ristya
Yang, Hsuan-Chia
author_facet Wang, Ching-Huan
Huang, Chih-Wei
Nguyen, Phung Anh
Lin, Ming-Chin
Yeh, Chih-Yang
Islam, Md. Mohaimenul
Rahmanti, Annisa Ristya
Yang, Hsuan-Chia
author_sort Wang, Ching-Huan
collection PubMed
description SIMPLE SUMMARY: Medications for chronic diseases, such as tatins, aspirin, metformin, and angiotensin-converting-enzyme inhibitors/angiotensin II receptor blockers, are studied for decades, and a vast body of previous research has suggested potential repurposing of these medications for cancer prevention. However, a limited number of studies have analyzed the effect of various combinations of these four medications/classes on cancer risks. This study, using large databases, aimed to comprehensively analyze the composite chemopreventive effects of all possible combinations of these four medications/classes. We found no synergistic effect of multiple use of these agents on cancer prevention in this study. Our results may provide information or inspiration for researchers or clinicians to conduct future research on combinations with cancer-preventive potential to further determine the optimal strategy for chemoprevention against cancer. ABSTRACT: Despite previous studies on statins, aspirin, metformin, and angiotensin-converting-enzyme inhibitors (ACEIs)/angiotensin II receptor blockers (ARBs), little has been studied about all their possible combinations for chemoprevention against cancers. This study aimed to comprehensively analyze the composite chemopreventive effects of all the combinations. In this case-control study, health records were retrieved from claims databases of Taiwan’s Health and Welfare Data Science Center. Eligible cases were matched at a 1:4 ratio with controls for age and sex. Both cases and controls were categorized into 16 exposure groups based on medication use. A total of 601,733 cancer cases were identified. Cancer risks (denoted by adjusted odds ratio; 99% confidence interval) were found to be significantly decreased: overall risk of all cancers in statin-alone (0.864; 0.843, 0.886), aspirin-alone (0.949; 0.939, 0.958), and ACEIs/ARBs (0.982; 0.978, 0.985) users; prostate (0.924; 0.889, 0.962) and female breast (0.967; 0.936, 1.000) cancers in metformin-alone users; gastrointestinal, lung, and liver cancers in aspirin and/or ACEIs/ARBs users; and liver cancer (0.433; 0.398, 0.471) in statin users. In conclusion, the results found no synergistic effect of multiple use of these agents on cancer prevention. Use of two (statins and aspirin, statins and metformin, statins and ACEIs/ARBs, and aspirin and ACEIS/ARBs) showed chemopreventive effects in some combinations, while the use of four, in general, did not.
format Online
Article
Text
id pubmed-8909564
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89095642022-03-11 Chemopreventive Effects of Concomitant or Individual Use of Statins, Aspirin, Metformin, and Angiotensin Drugs: A Study Using Claims Data of 23 Million Individuals Wang, Ching-Huan Huang, Chih-Wei Nguyen, Phung Anh Lin, Ming-Chin Yeh, Chih-Yang Islam, Md. Mohaimenul Rahmanti, Annisa Ristya Yang, Hsuan-Chia Cancers (Basel) Article SIMPLE SUMMARY: Medications for chronic diseases, such as tatins, aspirin, metformin, and angiotensin-converting-enzyme inhibitors/angiotensin II receptor blockers, are studied for decades, and a vast body of previous research has suggested potential repurposing of these medications for cancer prevention. However, a limited number of studies have analyzed the effect of various combinations of these four medications/classes on cancer risks. This study, using large databases, aimed to comprehensively analyze the composite chemopreventive effects of all possible combinations of these four medications/classes. We found no synergistic effect of multiple use of these agents on cancer prevention in this study. Our results may provide information or inspiration for researchers or clinicians to conduct future research on combinations with cancer-preventive potential to further determine the optimal strategy for chemoprevention against cancer. ABSTRACT: Despite previous studies on statins, aspirin, metformin, and angiotensin-converting-enzyme inhibitors (ACEIs)/angiotensin II receptor blockers (ARBs), little has been studied about all their possible combinations for chemoprevention against cancers. This study aimed to comprehensively analyze the composite chemopreventive effects of all the combinations. In this case-control study, health records were retrieved from claims databases of Taiwan’s Health and Welfare Data Science Center. Eligible cases were matched at a 1:4 ratio with controls for age and sex. Both cases and controls were categorized into 16 exposure groups based on medication use. A total of 601,733 cancer cases were identified. Cancer risks (denoted by adjusted odds ratio; 99% confidence interval) were found to be significantly decreased: overall risk of all cancers in statin-alone (0.864; 0.843, 0.886), aspirin-alone (0.949; 0.939, 0.958), and ACEIs/ARBs (0.982; 0.978, 0.985) users; prostate (0.924; 0.889, 0.962) and female breast (0.967; 0.936, 1.000) cancers in metformin-alone users; gastrointestinal, lung, and liver cancers in aspirin and/or ACEIs/ARBs users; and liver cancer (0.433; 0.398, 0.471) in statin users. In conclusion, the results found no synergistic effect of multiple use of these agents on cancer prevention. Use of two (statins and aspirin, statins and metformin, statins and ACEIs/ARBs, and aspirin and ACEIS/ARBs) showed chemopreventive effects in some combinations, while the use of four, in general, did not. MDPI 2022-02-25 /pmc/articles/PMC8909564/ /pubmed/35267516 http://dx.doi.org/10.3390/cancers14051211 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wang, Ching-Huan
Huang, Chih-Wei
Nguyen, Phung Anh
Lin, Ming-Chin
Yeh, Chih-Yang
Islam, Md. Mohaimenul
Rahmanti, Annisa Ristya
Yang, Hsuan-Chia
Chemopreventive Effects of Concomitant or Individual Use of Statins, Aspirin, Metformin, and Angiotensin Drugs: A Study Using Claims Data of 23 Million Individuals
title Chemopreventive Effects of Concomitant or Individual Use of Statins, Aspirin, Metformin, and Angiotensin Drugs: A Study Using Claims Data of 23 Million Individuals
title_full Chemopreventive Effects of Concomitant or Individual Use of Statins, Aspirin, Metformin, and Angiotensin Drugs: A Study Using Claims Data of 23 Million Individuals
title_fullStr Chemopreventive Effects of Concomitant or Individual Use of Statins, Aspirin, Metformin, and Angiotensin Drugs: A Study Using Claims Data of 23 Million Individuals
title_full_unstemmed Chemopreventive Effects of Concomitant or Individual Use of Statins, Aspirin, Metformin, and Angiotensin Drugs: A Study Using Claims Data of 23 Million Individuals
title_short Chemopreventive Effects of Concomitant or Individual Use of Statins, Aspirin, Metformin, and Angiotensin Drugs: A Study Using Claims Data of 23 Million Individuals
title_sort chemopreventive effects of concomitant or individual use of statins, aspirin, metformin, and angiotensin drugs: a study using claims data of 23 million individuals
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909564/
https://www.ncbi.nlm.nih.gov/pubmed/35267516
http://dx.doi.org/10.3390/cancers14051211
work_keys_str_mv AT wangchinghuan chemopreventiveeffectsofconcomitantorindividualuseofstatinsaspirinmetforminandangiotensindrugsastudyusingclaimsdataof23millionindividuals
AT huangchihwei chemopreventiveeffectsofconcomitantorindividualuseofstatinsaspirinmetforminandangiotensindrugsastudyusingclaimsdataof23millionindividuals
AT nguyenphunganh chemopreventiveeffectsofconcomitantorindividualuseofstatinsaspirinmetforminandangiotensindrugsastudyusingclaimsdataof23millionindividuals
AT linmingchin chemopreventiveeffectsofconcomitantorindividualuseofstatinsaspirinmetforminandangiotensindrugsastudyusingclaimsdataof23millionindividuals
AT yehchihyang chemopreventiveeffectsofconcomitantorindividualuseofstatinsaspirinmetforminandangiotensindrugsastudyusingclaimsdataof23millionindividuals
AT islammdmohaimenul chemopreventiveeffectsofconcomitantorindividualuseofstatinsaspirinmetforminandangiotensindrugsastudyusingclaimsdataof23millionindividuals
AT rahmantiannisaristya chemopreventiveeffectsofconcomitantorindividualuseofstatinsaspirinmetforminandangiotensindrugsastudyusingclaimsdataof23millionindividuals
AT yanghsuanchia chemopreventiveeffectsofconcomitantorindividualuseofstatinsaspirinmetforminandangiotensindrugsastudyusingclaimsdataof23millionindividuals